Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
暂无分享，去创建一个
M. Bickel | P. Cahn | J. Molina | W. Greaves | G. Rizzardini | Margaret Johnson | Princy N. Kumar | P. Sklar | H. Wan | Cristiana Morais | Z. Xu